Clinical trials: Recurrent Diffuse Large B-Cell Lymphoma
DLBCL
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a multicenter, open-label phase Ib study, evaluating the safety, tolerability, preliminary efficacy and PK characteristics of Rocbrutinib (LP-168) combined with R-GemOx in patients with R/R non-GCB DLBCL.
- Trial name
- NCT07570017
- Testing
- Rocbrutinib, R-GemOx
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Evaluation of efficacy, safety profile and tolerability of rituximab (MabThera) in combination with chemotherapy in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT02486952
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin
- Where
- 5 sites in Serbia
- Volunteers
- 154 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma (DLBCL)
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
- Trial name
- JULIET (NCT02445248)
- Testing
- Tisagenlecleucel, Lymphodepleting chemotherapy
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
- Trial name
- LOTIS-2 (NCT03589469)
- Testing
- Loncastuximab tesirine
- Where
- 37 sites in United States, Italy and 2 more
- Volunteers
- 145 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory…
- Trial name
- NCT00039156
- Testing
- ortataxel
- Where
- 15 sites in United States, Canada
- Sponsor
- Theradex
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or…
- Trial name
- NCT04442022
- Testing
- Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy)
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 501 people
- Sponsor
- Karyopharm Therapeutics Inc
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Diffuse Large B Cell Lymphoma
A Study of ICP-022 in Patients With R/R DLBCL
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL.
- Trial name
- DLBCL (NCT04438005)
- Testing
- ICP-022
- Where
- 7 sites in China
- Volunteers
- 3 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05068440
- Testing
- Zanubrutinib
- Where
- 25 sites in China
- Volunteers
- 65 people
- Sponsor
- BeiGene
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
- Trial name
- ALEXANDER (NCT03287817)
- Testing
- AUTO3
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Autolus Limited
Lymphoma, Large B-Cell, Diffuse (DLBCL)
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
NM-IL-12 is being evaluated as an immunotherapeutic with concomitant hematopoietic regenerating properties for treatment of relapsed/refractory DLBCL, an aggressive type of B-cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT02544724
- Testing
- NM-IL-12
- Volunteers
- 12 people
- Sponsor
- Neumedicines Inc.
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Lymphoma
Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal vincristine in treating patients who have…
- Trial name
- NCT00006383
- Testing
- liposomal vincristine sulfate
- Where
- 9 sites in United States, Canada
- Sponsor
- Inex Pharmaceuticals
Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
- Trial name
- NCT03372837
- Testing
- Rituximab
- Where
- 29 sites in Japan
- Volunteers
- 40 people
- Sponsor
- SymBio Pharmaceuticals
Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options.
- Conditions
- Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis
- Trial name
- NCT03886831
- Testing
- PRT543
- Where
- 23 sites in United States
- Volunteers
- 232 people
- Sponsor
- Prelude Therapeutics Incorporated
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part…
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- MT-3724NHL001 (NCT02361346)
- Testing
- MT-3724 Phase 1, MT-3724 Phase 2
- Where
- 41 sites in United States, Belarus and 8 more
- Volunteers
- 38 people
- Sponsor
- Molecular Templates, Inc.
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies.
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome
- Trial name
- NCT05665530
- Testing
- PRT2527, Zanubrutinib, Venetoclax
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Diffuse Large B-Cell Lymphoma
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: is…
- Trial name
- NCT05626322
- Testing
- Maplirpacept, Tafasitamab, Lenalidomide
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab